A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model

Journal of Pharmaceutical and Biomedical Analysis

Volumn 115, Issue , 2015, Pages 174-182

  Gong, Yingge ^a   Liu, Ying ^a   Zhou, Ling ^a   Di, Xin ^a   Li, Wei ^a   Li, Qing ^a   Bi, Kaishun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Animal model; Biomarkers; Metabonomics; Total ginsenosides

Indexed keywords

ACETYLCARNITINE; AMINO ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FORMIC ACID; GINSENOSIDE; HEXADECENOIC ACID; N EICOSANOYLETHANOLAMINE; PALMITOYLCARNITINE; PHYTOSPHINGOSINE; PROLINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VACCENYLCARNITINE; VALINE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; COGNITION; DOWN REGULATION; GINSENG; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PATTERN RECOGNITION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; BLOOD; DEVICES; DISEASE MODEL; DRUG EFFECTS; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INBRED MOUSE STRAIN; METABOLISM; METABOLOMICS; PROCEDURES; TANDEM MASS SPECTROMETRY;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; GINSENOSIDES; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; PRINCIPAL COMPONENT ANALYSIS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84937694919     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.07.007     Document Type: Article

References (50)

1. Xu X.H., Huang Y., Wang G., Chen S.D. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. Neurosci. Bull. 2012, 28:641-648.
2. Li N.J., Liu W.T., Li W., Li S.Q., Chen X.H., Bi K.S., He P. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 2010, 43:992-997.
3. Han X., Rozen S., Boyle S.H., Hellegers C., Cheng H., Burke J.R., Welsh-Bohmer K.A., Doraiswamy P.M., Kaddurah-Daouk R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011, 6:e21643.
4. Sato Y., Suzuki I., Nakamura T., Bernier F., Aoshima K., Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 2012, 53:567-576.
5. Graham S.F., Chevallier O.P., Roberts D., Hölscher C., Elliott C.T., Green B.D. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal. Chem. 2013, 85:1803-1811.
6. Salek R.M., Xia J., Innes A., Sweatman B.C., Adalbert R., Randle S., McGowan E., Emson P.C., Griffin J.L. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 2010, 56:937-947.
7. Hu Z.P., Browne E.R., Liu T., Angel T.E., Ho P.C., Chan E.C.Y. Metabonomic profiling of TASTPM transgenic Alzheimer's disease mouse model. J. Proteome. Res. 2012, 11:5903-5913.
8. Trupp M., Zhu H., Wikoff W.R., Baillie R.A., Zeng Z.B., Karp P.D., Eiehn O., Krauss R.M., Kaddurah-Daouk R. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PloS One 2012, 7:e38386.
9. Mook-Jung I., Hong H.S., Boo J.H., Lee K.H., Yun S.H., Cheong M.Y., Joo I., Huh K., Jung M.W. Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J. Neurosci. Res. 2001, 63:509-515.
10. Wang Y.Z., Chen J., Chu S.F., Wang Y.S., Wang X.Y., Chen N.H., Zhang J.T. Improvement of memory in mice and increase of hippocampal excitability in rats by ginsenoside Rg1's metabolites ginsenoside Rh1 and protopanaxatriol. J. Pharmacol. Sci. 2009, 109:504-510.
11. Li N., Liu B., Dluzen D.E., Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J. Ethnopharmacol. 2007, 111:458-463.
12. Zhang G., Liu A., Zhou Y., San X., Jin T., Jin Y. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. J. Ethnopharmacol. 2008, 115:441-448.
13. Kim M.S., Yu J.M., Kim H.J., Kim H.B., Kim S.T., Jang S.K., Choi Y.W., Lee D.I., Joo S.S. Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in neuro-2a cells. Biol. Pharm. Bull. 2014, 37:826-833.
14. Fang F., Chen X., Huang T., Lue L.F., Luddy J.S., Yan S.S. Multi-faced neuroprotective effects of ginsenoside Rg1 in an Alzheimer mouse model. BBA-Mol. Basis Dis. 2012, 1822:286-292.
15. Wang Y., Liu J., Zhang Z., Bi P., Qi Z., Zhang C. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci. Lett. 2011, 487:70-72.
16. Li X., Li M., Li Y., Quan Q., Wang J. Cellular and molecular mechanisms underlying the action of ginsenoside Rg1 against Alzheimer's disease. Neural Regener. Res. 2012, 7:2860.
17. Li Q. Study on exploitation of pharmacy of Aidi lyophilizer. Doctorate dissertation in Chinese 2006, 14-16. Shenyang Pharmaceutical University.
18. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
19. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., Vidal J., Van De Vorstenbosch C.A. Good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 2001, 21:15-23.
20. Jhoo J.H., Kim H.C., Nabeshima T., Yamada K., Shin E.J., Jhoo W.K., Kim W., Kang K.S., Jo S.A., Woo J.I. β-Amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 2004, 155:185-196.
21. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Vannucchi M.G., Rosi S., Pepeu G., Casamenti F. β-Amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobio. Dis. 2002, 11:257-274.
22. Shizuo N., Murayama N., Noshita T., Annoura H., Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta 1-42 amyloid peptide. Brain Res. 2001, 912:128-136.
23. Arikanoglu A., Akil E., Varol S., Yucel Y., Yuksel H., Cevik M.U., Palanci Y., Unan F. Relationship of cognitive performance with prolidase and oxidative stress in Alzheimer disease. Neurol. Sci. 2013, 34:2117-2121.
24. Cohen S.M., Nadler J.V. Proline-induced potentiation of glutamate transmission. Brain Res. 1997, 761:271-282.
25. Tsuruoka M., Hara J., Hirayama A., Sugimoto M., Soga T., Shankle W.R., Tomita M. Capillary electrophoresis mass spectrometry based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis 2013, 34:2865-2872.
26. Nah S.Y., McCleskey E.W. Ginseng root extract inhibits calcium channels in rat sensory neurons through a similar path, but different receptor, as (-type opioids. J. Ethnopharmacol. 1994, 42:45-51.
27. Liu M., Zhang J. Effects of ginsenoside Rb1 and Rg1 on synaptosomal free calcium level, ATPase and calmodulin in rat hippocampus. Chin. Med. J. Peking 1995, 108:544-547.
28. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.
29. Zadori D., Klivenyi P., Vamos E., Fülöp F., Toldi J., Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J. Neural Transm. 2009, 116:1403-1409.
30. Fekkes D., Van Der Cammen T.J.M., Van Loon C.P.M., Verschoor C., Van Harskamp F., De Koning I., Schudel W.J., Pepplinkhuizen L. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J. Neural Transm. 1998, 105:287-294.
31. Kaddurah-Daouk R., Zhu H., Sharma S., Bogdanov M., Rozen S.G., Matson W., Oki N.O., Motsinger-Reif A.A., Churchill E., Lei Z., Appleby D., Kling M.A., Trojanowski J.Q., Doraiswamy P.M., Arnold S.E. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl. Psychiatry 2013, 3:e244.
32. Schwarz M.J., Guillemin G.J., Teipel S.J., Buerger K., Hampel H. Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:345-352.
33. Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog. Lipid Res. 2010, 49:61-75.
34. Virmani A., Binienda Z. Role of carnitine esters in brain neuropathology. Mol. Aspects. Med. 2004, 25:533-549.
35. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Salsi A., Calogero P., Parma E., Stramba-Badiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favaretto M., Bozeglav C., Alberoni M., De Leo D., Serraiotto L., Baiocchi A., Scoccia S., Culotta P., Ieracitano D. Long-term acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 1991, 41:1726.
36. Zhou P., Chen Z., Zhao N., Liu D., Guo Z.Y., Tan L., Hu J., Wang Q., Wang J.Z., Zhu L.Q. Acetyl-L-carnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuv. Res. 2011, 14:669-679.
37. Wang X., Wang L.P., Tang H., Shan W.Y., Wang X., Liu D., Wu Y.Y., Tian Q., Wang J.Z., Zhu L.Q. Acetyl-l-carnitine rescues scopolamine-induced memory deficits by restoring insulin-like growth factor II via decreasing p53 oxidation. Neuropharmacology 2014, 76:80-87.
38. Kalaria R.N., Harik S.I. Carnitine acetyltransferase activity in the human brain and its microvessels is decreased in Alzheimer's disease. Ann. Neurol. 1992, 32:583-586.
39. Mutomba M.C., Yuan H., Konyavko M., Adachi S., Yokoyama C.B., Esser V., McGarry J.D., Babior B.M., Gottlieb R.A. Regulation of the activity of caspases by l-carnitine and palmitoylcarnitine. FEBS Lett. 2000, 478:19-25.
40. Maurer I., Zierz S., Möller H.J. Carnitine acyltransferases are not changed in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:71-76.
41. Lee H., Kim M., Shin S.S., Yoon M. Ginseng treatment reverses obesity and related disorders by inhibiting angiogenesis in female db/db mice. J. Ethnopharmacol. 2014, 155:1342-1352.
42. Fuchs B., Schiller J. Lysophospholipids: their generation, physiological role and detection. Are they important disease markers. Mini-Rev. Med. Chem. 2009, 9:368-378.
43. Chalbot S., Zetterberg H., Blennow K., Fladby T., Grundke-Iqbal I., Iqbal K. Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease. Clin. Chem. 2009, 55:2171-2179.
44. Angelini R., Vortmeier G., Corcelli A., Fuchs B. A fast method for the determination of the PC/LPC ratio in intact serum by MALDI-TOF MS: an easy-to-follow lipid biomarker of inflammation. Chem. Phys. Lipids 2014, 183:169-175.
45. Ramesh T., Kim S.W., Hwang S.Y., Sohn S.H., Yoo S.K., Kim S.K. Panax ginseng reduces oxidative stress and restores antioxidant capacity in aged rats. Nutr. Res. 2012, 32:718-726.
46. Söderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
47. Conquer J.A., Tierney M.C., Zecevic J., Bettger W.J., Fisher R.H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000, 35:1305-1312.
48. Lizard G., Rouaud O., Demarquoy J., Cherkaoui-Malki M., Iuliano L. Potential roles of peroxisomes in Alzheimer's disease and in dementia of the Alzheimer's type. J. Alzheimers Dis. 2012, 29:241-254.
49. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., Serhan C.N., Bazan N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115:2774-2783.
50. Fonteh A.N., Harrington R.J., Tsai A., Liao P., Harrington M.G. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 2007, 32:213-224.